Dana Zaborowski, NP
Adult Health · Liverpool, NYNPI 1538155387
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,959 of the $21,907 with a category attached, or 82.0%. 21 manufacturers reported payments, led by Boehringer Ingelheim at 50.6% of the total. Reporting peaked in 2024 at $7,420 and has fallen 60.7% since, to $2,912 in 2025. Among adult health clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 137 payments — averaging $159.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$11K
- Johnson & Johnson$5K
- Lilly USA, LLC$4K
- Merck$265
- AstraZeneca$219
- Amgen$143
- plus $993 from 15 others
What the payments were for
- Speaking & faculty fees$17,95982%
- Travel & lodging$7413%
- Food & beverage$3,16014%
- Education$460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 36 | $11,084 |
| Johnson & Johnson | 13 | $5,268 |
| Lilly USA, LLC | 14 | $3,935 |
| Merck | 14 | $265 |
| AstraZeneca | 10 | $219 |
| Amgen | 7 | $143 |
| Bridgebio Pharma, Inc. | 2 | $136 |
| Sanofi-aventis U.S. LLC | 5 | $130 |
| Novartis | 7 | $115 |
| Scpharmaceuticals Inc. | 5 | $100 |
| Boston Scientific | 3 | $97 |
| Pfizer | 5 | $77 |
| Bayer | 3 | $71 |
| Impulse Dynamics (USA) Inc. | 3 | $61 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $39 |
| Medtronic | 2 | $33 |
| Lexicon Pharmaceuticals, Inc. | 2 | $31 |
| Abiomed | 1 | $30 |
| Edwards Lifesciences | 1 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,907 in reported general payments places this provider in the 95th percentile of 3,828 adult health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 462 | $622,319 |
| EliquisApixaban | 505 | $607,718 |
| EntrestoSacubitril/Valsartan | 428 | $519,574 |
| JardianceEmpagliflozin | 255 | $281,529 |
| Repatha SureclickEvolocumab | 128 | $168,852 |
| FarxigaDapagliflozin Propanediol | 61 | $69,012 |
| MultaqDronedarone Hcl | 47 | $62,635 |
| Praluent PenAlirocumab | 22 | $23,791 |
| Metoprolol Succinate | 894 | $13,490 |
| BrilintaTicagrelor | 18 | $13,122 |
| Atorvastatin Calcium | 720 | $7,875 |
| Ezetimibe | 300 | $6,565 |
| Ranolazine ErRanolazine | 45 | $4,362 |
| Propafenone Hcl ErPropafenone Hcl | 18 | $4,325 |
| ClopidogrelClopidogrel Bisulfate | 302 | $4,246 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $5,268 | $622,319462 claims |
| PfizerEliquis | $77 | $607,718505 claims |
| NovartisEntresto | $115 | $519,574428 claims |
| Boehringer IngelheimJardiance | $11,084 | $281,529255 claims |
| AstraZenecaFarxiga, Brilinta | $219 | $82,13479 claims |
| Sanofi-aventis U.S. LLCMultaq | $130 | $62,63547 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,828 adult health providers in New York.
Other adult health in Liverpool
- Donna CatameroNew York$279K
- Kristen DurkinPort Jefferson Station$255K
- Mary CiechoskiBuffalo$200K
- Jennifer FioriniGlens Falls$151K
- Katelyn McCormackAmherst$131K
- Maria Gigante-BaggettEast Syracuse$92K
- Jane PattersonRochester$66K
- Alyson HartyNew York$65K
- Danielle BrunoPlainview$61K
- Julie PlantamuraPort Jefferson Station$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.